And designed the experiments: EEM JMS JJO. Performed the experiments: EEM

And designed the experiments: EEM JMS JJO. Performed the experiments: EEM LMH JR JMS JJO. Analyzed the data: EEM JR JJO.Contributed reagents/materials/analysis tools: EEM AC WKP JMS JJO. 10781694 Wrote the paper: EEM AC JR WKP JMS JJO.
Chronic obstructive pulmonary disease (COPD) is commonly accompanied by acute exacerbations (AECOPD), which contribute significantly to morbidity and mortality [1]. Currently, COPD is diagnosed based on the evidence of incompletely reversible airflow obstruction [1]. Furthermore, increased evidence has suggested that COPD is a multifactorial and multisystemic disease. Hence, multidimensional assessments are needed for the evaluation of disease severity. However, there are a few biomarkers available for the evaluation of AECOPD. AECOPD is usually caused by pathogen infection-related inflammation and other insults. During the process of AECOPD, pro-inflammatory stimuli in the lung recruit inflammatory cells, such as neutrophils, eosinophils, macrophages, and lymphocytes, leading to the destruction of lung parenchyma and remodelingmultiple components of the airway epithelial lumen. There are varying types of stimuli, which can recruit different types of inflammatory cells [2,3]. In addition, the different inflammatory phenotypes are also clinically relevant due to potential differences in the response to therapeutic interventions. Indeed, previous studies have shown that the effects of treatments are different in COPD patients with different distributions of eosinophil infiltration or with acute exacerbation [2,4,5], and during exacerbations, and differing inflammatory patterns based on pathogens and biomarkers have been reported [2,3]. Therefore, identification of the inflammatory phenotype in patients with AECOPD will be of great significance in understanding the disease process and in the management of patients with AECOPD. Inflammatory cells can secrete pro-inflammatory cytokines, chemokines, and proteases contributing to the pathogenesis of AECOPD and the development of emphysema [6,7]. PreviousSputum Cellular Phenotypes in AECOPDstudies have shown that the concentrations of inflammatory mediators, such as serum amyloid A (SAA), C-reactive protein (CRP), Interleukin-6 (IL-6), and matrix metalloproteinase-9 (MMP-9), are correlated with the severity and are associated with poor prognosis of AECOPD [8?0]. However, the relationship among the levels of inflammatory mediators, the predominant type of inflammatory infiltrates in the lungs, and the degrees of functional Title Loaded From File impairment in the lung has not been clarified in patients with AECOPD. Moreover, how AECOPD patients with differently predominate inflammatory infiltrates respond to standard therapies is still not fully understood. In this study, 83 AECOPD patients were recruited for examining the number of sputum inflammatory cells. Furthermore, these patients were stratified, according to the predominant type of inflammatory cell and their lung function and response to therapeutic treatments. Sputum and serum inflammatory mediators were examined to determine the potential association among the predominant type of inflammatory infiltrate, the levels of sputum and serum inflammatory mediators, and the 1676428 degree of functional impairment in the lung. We tested the hypotheses that airway inflammation in AECOPD patients is heterogenous and can be N-related peptides and their receptors elicit profound scratching like morphine in classified by the predominant type of sputum inflammatory infiltrate, which are associated with the degrees of functional impairment.And designed the experiments: EEM JMS JJO. Performed the experiments: EEM LMH JR JMS JJO. Analyzed the data: EEM JR JJO.Contributed reagents/materials/analysis tools: EEM AC WKP JMS JJO. 10781694 Wrote the paper: EEM AC JR WKP JMS JJO.
Chronic obstructive pulmonary disease (COPD) is commonly accompanied by acute exacerbations (AECOPD), which contribute significantly to morbidity and mortality [1]. Currently, COPD is diagnosed based on the evidence of incompletely reversible airflow obstruction [1]. Furthermore, increased evidence has suggested that COPD is a multifactorial and multisystemic disease. Hence, multidimensional assessments are needed for the evaluation of disease severity. However, there are a few biomarkers available for the evaluation of AECOPD. AECOPD is usually caused by pathogen infection-related inflammation and other insults. During the process of AECOPD, pro-inflammatory stimuli in the lung recruit inflammatory cells, such as neutrophils, eosinophils, macrophages, and lymphocytes, leading to the destruction of lung parenchyma and remodelingmultiple components of the airway epithelial lumen. There are varying types of stimuli, which can recruit different types of inflammatory cells [2,3]. In addition, the different inflammatory phenotypes are also clinically relevant due to potential differences in the response to therapeutic interventions. Indeed, previous studies have shown that the effects of treatments are different in COPD patients with different distributions of eosinophil infiltration or with acute exacerbation [2,4,5], and during exacerbations, and differing inflammatory patterns based on pathogens and biomarkers have been reported [2,3]. Therefore, identification of the inflammatory phenotype in patients with AECOPD will be of great significance in understanding the disease process and in the management of patients with AECOPD. Inflammatory cells can secrete pro-inflammatory cytokines, chemokines, and proteases contributing to the pathogenesis of AECOPD and the development of emphysema [6,7]. PreviousSputum Cellular Phenotypes in AECOPDstudies have shown that the concentrations of inflammatory mediators, such as serum amyloid A (SAA), C-reactive protein (CRP), Interleukin-6 (IL-6), and matrix metalloproteinase-9 (MMP-9), are correlated with the severity and are associated with poor prognosis of AECOPD [8?0]. However, the relationship among the levels of inflammatory mediators, the predominant type of inflammatory infiltrates in the lungs, and the degrees of functional impairment in the lung has not been clarified in patients with AECOPD. Moreover, how AECOPD patients with differently predominate inflammatory infiltrates respond to standard therapies is still not fully understood. In this study, 83 AECOPD patients were recruited for examining the number of sputum inflammatory cells. Furthermore, these patients were stratified, according to the predominant type of inflammatory cell and their lung function and response to therapeutic treatments. Sputum and serum inflammatory mediators were examined to determine the potential association among the predominant type of inflammatory infiltrate, the levels of sputum and serum inflammatory mediators, and the 1676428 degree of functional impairment in the lung. We tested the hypotheses that airway inflammation in AECOPD patients is heterogenous and can be classified by the predominant type of sputum inflammatory infiltrate, which are associated with the degrees of functional impairment.